Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations

July 16, 2019

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Francois, Laetitia Claire; Leffin, Melissa; Spinelli, Jennifer

  • IRB No: ACNS1721

    Protocol Abbrev: ACNS1721

    Principal Investigator: Don E. Eslin, MD

    Phase: Drug: Phase II

    Age Group: Pediatric

    Secondary Protocol No: ACNS1721

    Treatment: Drug: Temozolomide, Drug: Veliparib, Radiation Therapy

    Therapies Involved: Chemotherapy

    ClinicalTrials.gov ID: NCT03581292

  • Objective

    This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide may work better in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations.

  • Key Eligibility

    Sex/Gender

    Sexes Eligible for Study: All


    Ages
    3 Years to 25 Years (Child, Adult)